Hyperparathyroidism Pipeline Review, H2 2012 New Report
Hyperparathyroidism - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperparathyroidism.
View full press release